Research programme: GABA receptor modulators - Acorda Therapeutics

Drug Profile

Research programme: GABA receptor modulators - Acorda Therapeutics

Latest Information Update: 29 Jul 2009

Price : $50

At a glance

  • Originator Neurorecovery
  • Class
  • Mechanism of Action GABA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Epilepsy; Neurodegenerative disorders

Most Recent Events

  • 05 Feb 2008 Acorda Therapeutics acquires ownership of GABAmide® product from Neurorecovery
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top